MAUNA KEA TECHNOLOGIES Mauna Kea Technologies presents its Board of Directors consisting of international experts in innovative medical technologies.
PARIS, France - 11 June 2014 - Mauna Kea Technologies (Euronext: MKEA, FR0010609263, PEA-PME eligible), leader in the field of optical biopsy, today announced the completion of its anticipated Board of Directors reorganization. At today's Shareholder Meeting, Marie Meynadier and Jean-Luc Boulnois were elected to the Board of Directors replacing Creadev's nominees the Board, Bertrand de Talhouët and Marie- Laure Pochon, who are leaving the Board following the recent sale of Creadev's stake in the Company. The Company also announced that Gilles Brisson will be succeeded as Chairman of the Board by Christopher McFadden, an independent member of the Board since 2008. Current independent Board member Andre- Michel Ballester remains on the Board and Philippe Maes will no longer act as a Board observer.
Following these changes, the Board of Directors will consist of all independent directors along with Sacha Loiseau, the Founder and CEO of Mauna Kea Technologies. Importantly, all of the Board members are specialists in the field of medical technology and have extensive operating experience.
"I am pleased to welcome the new directors to the Board and congratulate Chris on his new role as Chairman. Our independent directors' operational and strategic expertise with innovative medical technology companies both in France and abroad will all be considerable assets to prepare the way for new milestones and to support Mauna Kea Technologies' growth. I would also like to thank our departing directors for their service to the Company," said Sacha Loiseau, Founder and CEO of Mauna Kea Technologies.
André-Michel Ballester is, since 2007, the CEO of Sorin Group, the largest European cardiovascular company and the world leader in medical technologies for cardiac surgery, a company he joined in 2004 as Head of the Cardiac Rhythm Management unit. Prior to that Mr Ballester held a number of senior positions, including V ice-President EMEA, Asia and Latin America at Edwards Lifesciences, a US manufacturer of products for treating cardiovascular diseases. For more than a decade, he also held several executive positions in Europe and the USA. Also a member of the Board of Directors of both Carmat and Pixium V ision, Mr Ballester has a degree in Engineering from École Centrale in Lille and an MBA from INSEAD.
Jean-Luc Boulnois is the Executive Chairman of the Board at Microline Surgical, an innovative minimally- invasive surgical instrument company with which he has been involved for 18 years as an investor and then, from 2005 to 2013 as CEO, heading a period of uninterrupted growth. He was also CEO of Sometec from 1995 to 1999 and President and COO of Technomed International from 1989 to 1994, two medical technology companies. With French and American dual citizenship, Mr Boulnois has been living in Boston for close to 30 years. He holds a PhD in Aerospace Engineering from Princeton University and an Executive MBA from HEC.
Christopher McFadden is the founder of the Canyon Healthcare Partners, an investment fund. Between 2008 and 2013, he was a Managing Partner at Health Evolution Partners, an American healthcare-focused private equity fund. Between 1999 and 2008, he was Senior Financial Analyst at Goldman, Sachs & Co. in New York before heading healthcare-sector investment activities for Goldman Sachs' Americas Special Situations Group (AmSSG). Mr. McFadden is also a Trustee for Montefiore Medical Center in New York and the Natural History Museum of the Adirondacks.
Marie Meynadier is the CEO of EOS Imaging (Euronext: EOSI, FR0011191766). She began her career at the prestigious Bell Labs, and then steered the management of major development programs in France in the
fields of electronics, optics and microelectronics, which led to the creation of several start-ups. Marie Meynadier is a graduate of Sup Telecom and has a PhD in Physics from École Normale Supérieure on rue d'Ulm, Paris.
Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops, and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI tract, biliary and pancreatic duct, lungs, and during fine needle aspiration procedures. Cellvizio has also been cleared by SFDA in China and MHLW in Japan for use in the GI, respiratory and urinary tract.
For more information on Mauna Kea Technologies, visit www.maunakeatech.com
Westwicke Partners Investor Relations US Mark KlausnerTel: 443 213 0501
mark.klausner@westwicke.com
Investor Relations Europe
Florent Alba
Tel: +33 (0) 1 44 71 94 94
maunakea@newcap.fr
|
distributed by
|
